Related Experiment Video

Updated: Jun 27, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer: A Systematic Review with Meta-Analysis of

Marcelino Pérez-Bermejo1, Marcelo Mazón-Albalate2, María Teresa Murillo-Llorente1

  • 1SONEV Research Group, Faculty of Medicine and Health Sciences, Catholic University of Valencia San Vicente Mártir, C/Quevedo No. 2, 46001 Valencia, Spain.

Cancers
|June 26, 2026
PubMed
Abstract

Insights

Sacituzumab govitecan (SG) demonstrates significant activity in metastatic triple-negative breast cancer (mTNBC), aligning with both clinical trials and real-world data. This analysis synthesizes evidence to confirm SG

Area of Science:

  • Oncology
  • Clinical Pharmacology
  • Evidence Synthesis

Background:

  • Metastatic triple-negative breast cancer (mTNBC) presents a significant clinical challenge with limited therapeutic options.
  • Sacituzumab govitecan (SG), an antibody-drug conjugate targeting Trop-2, has emerged as a potential treatment.
  • A comprehensive synthesis of randomized and real-world evidence for SG in mTNBC, particularly in diverse patient groups, was needed.

Purpose of the Study:

  • To quantitatively summarize the comparative benefit of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC).
  • To assess the consistency of SG's efficacy observed in clinical trials with its performance in routine clinical practice.
  • To evaluate SG's effectiveness in underrepresented patient subgroups within mTNBC.

Main Methods:

  • Systematic literature review adhering to PRISMA 2020 guidelines, searching PubMed/MEDLINE and Web of Science (January 2017-April 2026).
  • Inclusion of randomized controlled trials and observational cohorts evaluating SG monotherapy in mTNBC.
  • Meta-analysis of single-arm efficacy data (objective response rate, clinical benefit rate, progression-free survival, overall survival) using random-effects models; risk of bias assessment using RoB 2 and ROBINS-I.

Main Results:

  • Nine studies (1242 patients) were included: one randomized trial (ASCENT) and eight real-world studies.
  • In the ASCENT trial, SG significantly improved progression-free survival (PFS) and overall survival (OS) compared to chemotherapy.
  • Pooled real-world data showed objective response rates of 31.1% and median PFS of 4.8 months, consistent with trial findings. Benefit was observed in older patients and Black women but not in those with brain metastases.

Conclusions:

  • Sacituzumab govitecan (SG) exhibits clinically meaningful activity in mTNBC, with consistent efficacy across controlled trials and real-world settings.
  • The comparative advantage of SG over chemotherapy is primarily established by the single ASCENT randomized trial.
  • Pooled single-arm data confirm SG's activity and its consistency in diverse mTNBC patient populations.
Keywords:
antibody–drug conjugatesmeta-analysisprogression-free survivalreal-world evidencesacituzumab govitecantriple-negative breast neoplasms

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.